Tag - monoclonal antibodies
02Feb

Provider Alert! Update to Texas Medicaid and CHIP Coverage for Monoclonal Antibody Therapy Procedure Code Q0222 for the Treatment of COVID-19

Date: February 2, 2023 Attention: All Providers Effective date: August 15, 2022 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action: Effective August 15, 2022, payment allowance was added for COVID-19 Monoclonal Antibody Therapy Q0222 Injection, Bebtelovimab, 175 mg claims. How this impacts providers: On November 30, 2022, the...

By OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , , , 0 CommentsRead more...
06Jul

Provider Alert! Monoclonal Antibody Procedure Code Q0221 for Treatment of COVID-19 Added to Texas Medicaid Benefits

Date: July 5, 2022 Attention: All Providers   Effective Date: February 24, 2022 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated with the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action: On February 24, 2022, the Centers for Medicare and Medicaid Services (CMS) created a new procedure code, Q0221, reflecting a revised U.S. Food and Drug...

By OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , , , , 0 CommentsRead more...
Provider Alert!
30Jun

Provider Alert! Tezspire (Tezepelumab-ekko) Update Effective July 1

Date: June 28, 2021 Attention: All Providers Effective Date: July 1, 2022 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. TCHP will apply updates and reprocess impacted claims as soon as possible. However, please allow up to sixty (60) business days for reprocessing. Providers are not required to appeal...

By Facilities, OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , , 0 CommentsRead more...
13Jun

Provider Alert! TMPPM Update for Monoclonal Antibodies Benralizumab, Mepolizumab, and Reslizumab

Date: May 24, 2022 Attention: All Providers Effective Date: April 1, 2022 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated with the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action: Beginning April 1, 2022, Texas Medicaid & Healthcare Partnership (TMHP) will update the Texas Medicaid Provider Procedures Manual, Outpatient Drug Services Handbook section 7.57.5, “Prior Authorization for Omalizumab,...

By Facilities, OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , 0 CommentsRead more...
04Feb

Provider Alert! Monoclonal Antibody Therapy Procedure Codes for COVID-19 Treatment Added to Texas Medicaid Benefits

Date: February 2, 2022 Attention: All Providers Effective Date: December 8, 2021 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action: On December 8, 2021, the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for the AstraZeneca product Evusheld (tixagevimab co-packaged with cilgavimab),...

By OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , , , , 0 CommentsRead more...